Patent US4312866A successfully refreshed from Google Patents.
US4312866A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of rifamycin SV and its related salts in the treatment of rheumatoid arthritis, and related formulations suited for the purpose
Assignee: Gruppo Lepetit SpA
•
Filing: 1980-07-07
•
Granted: 1982-01-26
•
Expires: 2000-07-07
Abstract
Abstract The invention concerns new salts of rifamycin SV and a new use of rifamycin SV in the treatment of rheumatoid arthritis and analogous affections, by intra-articular injection of the sodium salt of rifamycin SV or, better, of salts of said anti-biotic with basic aminoacid, e.g. with arginine, lysine or histidine.
Inventors
- 👤 Innocenzo Caruso
- 👤 Franco Montrone
- 👤 Luigi Molteni
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 03:10
CPC Classifications
C; C07; C07D; C07D233/00; C07D233/54; C07D233/64
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
9 words
The salt of rifamycin SV with a basic aminoacid.
Claim 2
Dependent Claim
9 words
The salt of rifamycin SV with a basic aminoacid.
Claim 3
Dependent Claim
7 words
The salt of rifamycin SV with arginine.
Claim 4
Dependent Claim
7 words
The salt of rifamycin SV with arginine.
Claim 5
Dependent Claim
7 words
The salt of rifamycin SV with lysine.
Claim 6
Dependent Claim
7 words
The salt of rifamycin SV with lysine.
Claim 7
Dependent Claim
7 words
The salt of rifamycin SV with histidine.
Claim 8
Dependent Claim
7 words
The salt of rifamycin SV with histidine.
Claim 9
Independent Claim
51 words
The method of treatment of a joint affected by rheumatoid arthritis, which consists of administering to a patient affected with a form of rheumatoid arthritis in a joint by means of intra-articular injections into the affected joint of rifamycin SV or salt thereof in the amount of 200-1000 mgs per injection.
Claim 10
Independent Claim
51 words
The method of treatment of a joint affected by rheumatoid arthritis, which consists of administering to a patient affected with a form of rheumatoid arthritis in a joint by means of intra-articular injections into the affected joint of rifamycin SV or salt thereof in the amount of 200-1000 mgs per injection.
Claim 11
Dependent Claim
14 words
The method according to claim 5, wherein the injection is administered once per week.
Claim 12
Dependent Claim
26 words
The method according to claim 5, wherein an aqueous solution of rifamycin SV, in a salified form, is injected into the affected joint of said patient.
Claim 13
Dependent Claim
26 words
The method according to claim 5, wherein an aqueous solution of a salt of rifamycin SV with a basic aminoacid is injected into the affected joint.
Claim 14
Dependent Claim
15 words
The method according to claim 8, wherein the rifamycin SV salt is the arginine salt.
Claim 15
Dependent Claim
15 words
The method according to claim 8, wherein the rifamycin SV salt is the lysine salt.
Claim 16
Dependent Claim
15 words
The method according to claim 8, wherein the rifamycin SV salt is the histidine salt.
Claim 17
Dependent Claim
21 words
The method according to claim 7, wherein the aqueous solution of rifamycin SV, in a salified form, is free from additives.
Claim 18
Dependent Claim
33 words
The method according to claim 7, wherein the aqueous solution is prepared at the very moment of use by dissolving in water the desired dose of a substantially anhydrous salt of rifamycin SV.
Claim 19
Dependent Claim
32 words
A formulation for the treatment of rheumatoid arthritis by an intra-articular injection of rifamycin SV, consisting of an aqueous solution of 200-1000 mgs. of a rifamycin SV salt with a basic aminoacid.
Claim 20
Dependent Claim
32 words
A formulation for the treatment of rheumatoid arthritis by an intra-articular injection of rifamycin SV, consisting of an aqueous solution of 200-1000 mgs. of a rifamycin SV salt with a basic aminoacid.
Claim 21
Dependent Claim
12 words
A formulation according to claim 14, wherein the basic aminoacid is arginine.
Claim 22
Dependent Claim
12 words
A formulation according to claim 14, wherein the basic aminoacid is lysine.
Claim 23
Dependent Claim
12 words
A formulation according to claim 14, wherein the basic aminoacid is histidine.
Claim 24
Dependent Claim
14 words
A formulation according to claim 14, wherein the aqueous solution is free from additives.
Claim 25
Dependent Claim
27 words
A formulation according to claim 14, wherein the aqueous solution is prepared extemporaneously dissolving in water the substantially anhydrous salt of rifamycin SV with a basic aminoacid.
References Cited (Backward Citations)
GB924472A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-01-25 | 1985-07-27 | 1986-01-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-01-25 | 1989-07-27 | 1990-01-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-01-25 | 1993-07-27 | 1994-01-26 | $7700.00 | Window Closed / Lapsed |